Expert Interview
Discussing the potential of gene therapies for dry AMD patients, including RegenXbio's RGX-314, for the treatment of dry AMD, DR and additional chronic retinal conditions.
Ticker(s): RGNX, ABBVInstitution: Keystone Retina Associates
- Board-certified ophthalmologist specializing in complex vitreo retinal surgery and medical retinal conditions
- Manages 600 patients with wet-AMD, 250 patients with presbyopia, and 500 patients with geograpgic atrophy.
- An accomplished clinician, published author, researcher, lecturer, and investigator in national clinical trials studying new therapies for macular degeneration, diabetic macular edema, and retinal vein occlusion. .
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
